Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-2070
Full Text
Open PDFAbstract
Available in full text
Date
February 3, 2014
Authors
Publisher
American Association for Cancer Research (AACR)